(firstQuint)Bioavailability of KD025 in Healthy Male Subjects Completed in the UK.

 A 200 mg tablet formulation of KD025 is being developed at Quotient Clinical to replace the capsule formulation.

 This Phase I study will evaluate the clinical performance of the tablet formulation in the fasted and fed states, in comparison to the capsule formulation in the fed state.

.

 Bioavailability of KD025 in Healthy Male Subjects Completed in the UK@highlight

Bioavailability, Phase I study to evaluate the clinical performance of the tablet formulation in the fasted and fed states, in comparison to the capsule formulation in the fed state.

